Novo Nordisk A/S (NVO.N)
4 May 2016
(This April 28 story corrects the fifth paragraph to say that two, not one, other diabetes drugs have positive cardiovascular side-effects)
April 29 Denmark's Novo Nordisk posted slightly stronger-than-expected first-quarter operating profit but trimmed its 2016 guidance due to lower currency exchange rates.
* Says semaglutide significantly reduces the risk of major adverse cardiovascular events in Sustain 6 trial
March 29 - The following stocks may be affected by newspaper reports and other factors on Tuesday:
LONDON Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.
LONDON, March 1 Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.
COPENHAGEN, Feb 12 Novo A/S, the parent company behind the world's largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month.
* Novo Nordisk A/S: proposed changes in composition of the board of directors of Novo Nordisk
* Italian lenders lead bank sector lower (Adds details, updates prices)
COPENHAGEN, Feb 3 Novo Nordisk on Wednesday lowered its target for long-term profit growth after a slightly weaker than expected fourth quarter.